Thermo Fisher Scientific Revenue increased by 6.2% to $11.01B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.2%, from $10.36B to $11.01B. Over 3 years (FY 2021 to FY 2024), Revenue shows relatively stable performance with a 3.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growth in market share or higher demand, while a decrease may signal market saturation or competitive pressure.
Represents the total consideration received from customers for the sale of goods or services, excluding any sales-relate...
Standard across all public companies; comparable to 'Net Sales' or 'Total Revenue' at peer distributors.
other_revenue_from_contract_with_customer_excluding_asse_0d5b70| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.27B | $9.33B | $10.70B | $11.82B | $10.97B | $10.68B | $11.45B | $10.71B | $10.69B | $10.57B | $10.89B | $10.35B | $10.54B | $10.60B | $11.40B | $10.36B | $11.01B |
| QoQ Change | — | +0.6% | +14.7% | +10.4% | -7.2% | -2.7% | +7.2% | -6.5% | -0.2% | -1.1% | +3.0% | -5.0% | +1.9% | +0.5% | +7.5% | -9.0% | +6.2% |
| YoY Change | — | — | — | — | +18.3% | +14.4% | +7.0% | -9.4% | -2.6% | -1.0% | -4.9% | -3.4% | -1.4% | +0.2% | +4.7% | +0.2% | +6.2% |